Increased spending on high cost drugs and reduced savings from generics responsible for 6.3% average growth over 2 years.
OTTAWA, Sept. 11, 2018 /CNW/ - The most recent edition of the Patented Medicine Prices Review Board's (PMPRB) CompassRx report found that public drug plan expenditures increased by an additional 1.9% in 2016-17, following a notable growth of 10.8% in 2015-16,
The increase in public plan drug costs in 2016-17 was driven by a greater use of higher-cost drugs combined with reduced generic savings and a decline in the use of direct-acting antiviral (DAA) drugs for hepatitis C. Higher-cost drugs (other than DAAs) continue to be the most pronounced driver, pushing costs upward by 4.4% in 2016-17.
The 4th edition of CompassRx was released today by the PMPRB through the National Prescription Drug Utilization Information System (NPDUIS) research initiative. This flagship report examines public drug plan expenditures in Canada and identifies the main factors driving annual changes in prescription drug expenditures. The following public drug plans are included in this study: British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, New Brunswick, Nova Scotia, Prince Edward Island, Newfoundland and Labrador, Yukon and Health Canada's Non-Insured Health Benefits Program.
CompassRx, 4th edition: 2016-17 is available on the PMPRB website in PDF and accessible HTML formats.
Follow us on Twitter: @PMPRB_CEPMB
SOURCE Patented Medicine Prices Review Board
Subscribe to our Free Newsletters!
Prunes are dried plums that are packed with nutrients like vitamins and minerals that are essential ...
Take the quiz on Rabies and test your knowledge about this infection that can affect the brain ...
Pneumonitis usually refers to inflammation of lung tissue due to various non-infective causes such ...View All